News

FSHD is a severe, rare genetic myopathy with an immune component for which there are currently no approved treatments. Being developed as an intravenous protein therapeutic for the

DCR-PH1 is the company’s proprietary DsiRNA-EX-based therapeutic candidate being developed for the treatment of PH1, which often results in kidney failure, and for which there are no approved

Idarucizumab is currently being investigated to specifically reverse the anticoagulant effect of dabigatran, the active ingredient in Pradaxa (dabigatran etexilate mesylate) in patients needing emergency intervention or experiencing

Tong, which is focused on the production, marketing and distribution of health sciences products, has a manufacturing facility located in Tongxiang, China. As part of the deal, Tong

The company is focused on developing and commercializing new medicines for the treatment of vitreo-retinal diseases. RVO is the third indication the company has underway for Jetrea. The

Avycaz is a combination of ceftazidime, a cephalosporin, and avibactam, a non-beta-lactam beta-lactamase inhibitor. The company said that currently only limited clinical safety and efficacy data for Avycaz

The trials will be carried out with one of Juno’s investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune’s investigational programed cell death ligand 1 (PD-L1)

The tablets are indicated to treat chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. The virus affects over 100 million

The open-label, multicenter, dose-escalation Phase I trial is designed to evaluate an intravenous (IV) formulation of marizomib in combination with bevacizumab (Avastin) in these patients. Patient enrollment is